As Seen In

"Given the sheer number of knee and hip replacement procedures every year, the fact that joint reconstruction technology has remained unchanged for over 50 years is perplexing."

- Newsweek

"Monogram has a first-to-market advantage in a sector that's about to get even more competitive."

- Zero Hedge

"Monogram Orthopedics is ushering in personalized orthopedic care by combining proprietary 3D printing technology with next-generation navigated surgical robotics".

- Inc.

"Monogram is developing a better way by commercializing highly personalized joint implants unique to every patient and a first-of-its-kind active robotics system that performs precise bone cuts."

- Fast Company

"Monogram has conducted studies with UCLA and demonstrated Monogram process was about seven times more stable than current hip replacement techniques."

- Futurism

The Direct Monogram Offering

While our common stock is publicly traded on the Nasdaq, we’re offering you an investment option that includes an 8.00% Series D Convertible Cumulative Preferred Stock per share (the “Series D Preferred Stock”) and one Common Stock Purchase Warrant. Each investment unit includes:

Investment Opportunity Includes:

1 Series D Preferred Stock

Preferred stock with an 8% annual dividend yield.

WITH

1 Warrant for Common Stock:

A 12-month stock purchase warrant to purchase one share of our common stock.

Term Sheet

Preferred Stock Offering Terms

1

8% Series D Convertible Cumulative Preferred Stock at an offering price of $2.25 and one $3.375 Common Stock Purchase Warrant

2
Year 0Year 1Year 2Year 3Total Return
Initial Investment$2.25
Annual Dividend$0.18$0.18$0.18$0.54
Redemption Value$3.38$3.38
Warrant Value ( Black Scholes1)$3.37
3 Year Convertible Preferred - 8.0% Coupon, Converts at 150% of face in 3 years2
Total Return: 91.3%
Simple Annualized: 39.4%
RRI: 24.1%
3

At any time, Series D Preferred Stock is convertible one-for-one into shares of our Common Stock at the option of the holder.

1. As of 6/24/2024 close, 25% illiquidity discount, 130% historical volatility, 4.5% RFR
2. Assumes redemption of convertible preferred, dividend payable in cash or shares, mandatory conversion at 125% of offering price for 10 consecutive trading days

Invest Now

What Do We Do?

We Aim to Combine High Precision Next Gen Robotics With Personalized Implants.

Personalized Implants
Precision Robot
A Perfect Fit

Why it is
DIFFERENT?

“Monogram is iPhone 5.
The Competition is Still an iPhone 1.”

Dr Robert Jamieson
The Orthopedic Specialty Center of Northern California
Efficent Case Planning
Fast Registration
Fast Cutting
Advanced Imagining
Platform Capability
All Integration
X
X
X
X
X
X
X
X

Differentiating Factors

Patient-specific boundaries (safety)
Active Sagittal Cutting
Non-invasive tracking*
Fortessed IP
AR Integrations
Personalized implants
*In development pipeline

Investment Catalysts

Monogram’s Primary Addressable Market, Robotically Prepared Cementless Knees, Remains Underpenetrated and Could Double in the Next Five to 10 years

The Share of Robots Used in Joint Replacements is Still Low

Cementless Knee Market is a Rapidly Growing Monopoly

1. 50% of Knee Replacements Could Be Robotic by 2027

By 2027, 50% of all knee replacements will be robotic, up from just 12% today. We hope to capture a fraction of this massive $19.4B market by having the first active navigated robotic arm.
Trends in Total Hip Constructions 2013-2022
Summary
1999
2010
2021
2022
Coated Hip System ( Cons 02,02a,03,03a)
40%
92%
96%
94%
Uncoated Hip Systems ( Cons 04,05)
54%
7%
4%
4%
Source: CRN 2013-2022. Includes shares of procedures for selected IDNs

2. Cementless Hips Became the Standard of Care vs. Cemented Hips Within a Decade

Cementless knee utilization is only 17% today.

3. Robotics Could Become the Standard of Care

Only 12% of TKA's are robotic, 3% of hips, 3% of shoulders.
Percentage of Joint Replacement Cases Utilizing Robots

4. Current One Size Fits None Paradigm Makes No Sense. 3D Printing Could Change the Game

High inventory burden is wasteful; two leading companies average 456 average days sales in inventory

Comparable Company Analysis

Getting FDA approval for devices has been a major catalyst for other companies. Before Mako received approval for limited sales of their machines, the company’s valuation was roughly $184M. Stryker acquired them for $1.7B in 2013. Zimmer paid $132M for Rosa, a French surgical navigation company whose technology was in pre-approval stage for TKA.* At an approximate market cap of $65M, and given the technological advancements we’re pioneering and getting certified, we feel Monogram has ample room to grow.
Company
Value
Details
Monogram
$65M
Planned submission 2024
Bluebelt (Smith & Nephew)
$132M
Post-clearance acquisition with limited sales
Mako (Stryker)
$184M
IPO valuation post clearance limited sales ($1.7B acqusition)
Rosa(Zimmer)
$275M
Pre-clearance for TKA

*These comparable companies may not be similar to Monogram Technologies nor indicative of future performance.

The Opportunity

Stryker has demonstrated superior performance compared to its industry peers since acquiring Mako. Management believe that this presents an opportunity for Monogram to add value.

Roadmap

2024
  • Anticipated completion of V&V
  • Direct Investment Offering
  • Anticipated FDA 510(k) submission
  • Anticipated submission for OUS clinical trial
Support Our Commercialization With a Direct Investment
Invest Now

Our Business Model

Easy to adopt technology with built-in annual revenue

Capital Equipment (the razor)

  • Surgical robot cart and tracking cart
  • Cutting system
  • Surgical Instrumentation

Consumables (the razorblades)

  • Implants - primary TKA includes femur, tibia and insert
  • Cutting tools ( blades) & Navigation

Requring Licensing Annuity

  • Price target 10% of capital equipment revenue annualy
  • Additional extended warranty

Target ASP:

$500,000

  • Surgical robot cart and tracking cart
  • Cutting system
  • Surgical Instrumentation

Target ASP:

$5,000

  • Implants - primary TKA includes femur, tibia and insert
  • Cutting tools ( blades) & Navigation

Target ASP:

$50,000

  • Price target 10% of capital equipment revenue annualy
  • Additional extended warranty

5 - Year Margin Targets

Robot Systems

Consumables

License

Billing Cycle

Once-off

Per Precedure

ARR

Gross Margin

55%

65%

70%

A World Class Team

Our team of extraordinary individuals is on a mission to revolutionize the world of orthopedic medicine, led by experts in running and scaling major tech and medical companies.
Douglas Unis, MD
FOUNDER & CHIEF MEDICAL OFFICER
Benjamin Sexson
CFA, CHIEF EXECUTIVE OFFICER
Kamran Shamaei, PhD
CHIEF TECHNOLOGY OFFICER
Noel Knape
CPA, CHIEF FINANCIAL OFFICER
Muhammad Afnan
DIRECTOR OF SOFTWARE ENGINEERING
Robert Jamieson, DO
BOARD CERTIFIED ORTHOPAEDIC SURGEON AT THE ORTHOPEDIC SPECIALTY CENTER OF NORTHERN CALIFORNIA
Edward M Adler, MD
CHAIR OF THE DEPARTMENT OF ORTHOPEDIC SURGERY AT MOUNT SINAI DOWNTOWN
Gregory Catlett, MD
TOTAL JOINT REPLACEMENT SPECIALIST AT ORTHOPAEDIC SPECIALISTS OF AUSTIN

Don't Miss an Update.

Subscribe to our newsletter to keep up with the latest updates and news from Monogram Orthopedics.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

See More from Monogram

Press

Monogram Makes Orthopedic History! Fully Remote Robotic Surgical Demo

Read More

Monogram Orthopaedics Inc. is pleased to announce the completion of its first pre-submission meeting with the U.S. Food and Drug Administration

Read More

Monogram Orthopaedics' Next Generation Surgical Robotic System Enters Verification Phase

Read More

How We're Managing Our Money

Read More

Monogram Orthopaedics Delivers First Surgical Robot

Read More
$2.25
Per Unit
Invest Now